In this article, we will list the 5 Best AI Driven Biotech Stocks to Invest In. Please visit 10 Best AI Driven Biotech Stocks to Invest In if you’d like to see an extended list and how we came up with the list of best AI driven biotech stocks.

5. IDEAYA Biosciences Inc. (NASDAQ:IDYA)

IDEAYA Biosciences Inc. (NASDAQ:IDYA) is one of the 10 best AI driven biotech stocks to invest in.

On June 3, in order to study the safety and efficacy of IDE892 in conjunction with Roche’s pan-RAS inhibitor, RG6505, in patients with MTAP-deleted pancreatic ductal adenocarcinoma, Ideaya Biosciences Inc. (NASDAQ:IDYA) and Roche (RHHBY) formed a clinical partnership. Roche will provide RG6505 for the investigation, and Ideaya will oversee and finance the combination experiment.

Whether used separately or in combination, both firms will keep all commercial licenses to their individual treatments. Ideaya and Roche will share governance of the cooperation. Subject to both firms’ approval, the agreement also allows for the evaluation of a three-drug combination that comprises IDE892, RG6505, and IDE397, Ideaya’s Phase 2 MAT2A inhibitor.

On June 1, IDEAYA Biosciences (NASDAQ:IDYA) shared its full Phase 2/3 data for its skin cancer drug trial at the ASCO meeting. The global study evaluated 313 patients, and the big news is that their new drug combination cut the risk of the disease getting worse by 58%.

Patients on the new treatment went 6.9 months without the disease progressing, compared to only 3.1 months for patients on standard treatments. The technical data also showed a major increase in response rates above 37% versus 5.8%, alongside a 73.3% disease control rate compared to 31.1% for the control group.

The company is already working on its official FDA application under a real-time review program, and they expect to finish submitting everything in the second half of 2026. The drug was mostly safe, and very few people stopped taking it. Final survival data is not ready yet, but the early trends look promising.

IDEAYA Biosciences Inc. (NASDAQ:IDYA) is a precision medicine oncology company, offering antibody drug inhibitors such as IDE161, IDE705, IDE397, IDE892, and more. The company also offers Darovasertib in multiple clinical trials and provides preclinical research programs focused on pharmacological inhibition. These include the INQUIRE chemical library and the HARMONY machine-learning engines.

4. Mineralys Therapeutics Inc. (NASDAQ:MLYS)

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 best AI driven biotech stocks to invest in.

On June 3, Mineralys Therapeutics (NASDAQ:MLYS) shared a major update regarding its blood pressure drug, lorundrostat. The company is repurchasing its potential royalty payments from Tanabe Pharma Corporation. Mineralys is paying $200 million upfront and up to $100 million later based on commercial milestones.

This moves their total possible future milestone payments to Tanabe up to $265 million, which includes the $100 million in new milestones and $165 million in old milestones, with up to $10 million tied to a second indication. Tanabe will also hand over the intellectual property rights for the drug.

To fund this, Mineralys initiated a $500 million agreement for a senior secured term loan with Pharmakon Advisors that matures in June 2031. They are getting $100 million of that debt immediately at closing, and the rest will come in three separate tranches. The interest rate is based on SOFR with a 3.25% floor, plus a 5.50% annual margin. On top of the loan, Mineralys also priced a separate stock offering to sell about $150 million of its common stock to help cover the upfront costs.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) engages in the development of therapeutics that target illnesses caused by dysregulated aldosterone. It is working on the development of lorundrostat, an aldosterone synthase inhibitor for cardiorenal conditions. These include chronic kidney disease, hypertension, and obstructive sleep apnea.

3. Dyne Therapeutics Inc. (NASDAQ:DYN)

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 best AI driven biotech stocks to invest in.

On June 3, enrollment for the Phase 1/2 ACHIEVE trial’s registrational expansion cohort, which evaluates z-basivarsen (DYNE-101) in individuals with myotonic dystrophy type 1 (DM1), has concluded, according to a statement from Dyne Therapeutics Inc. (NASDAQ:DYN). The business sees this as a significant step in developing what it thinks may be a best-in-class medication meant to address the disease’s wide range of symptoms.

According to Chief Medical Officer Doug Kerr, data from the cohort is anticipated in the first quarter of the next year and may show significant improvements in myotonia coupled with favorable trends in important functional metrics. Kerr stated:

“Completing enrollment in the registrational expansion cohort of ACHIEVE is a critical milestone as we advance a potentially best-in-class therapy designed to address the multi-system nature of DM1. With data from this cohort expected in the first quarter of next year, we believe we are well positioned to show a significant improvement in myotonia and trends on important functional outcomes to support a potential submission for U.S. Accelerated Approval. We expect that the strong interest we have seen in z-basivarsen will support enrollment in the ongoing confirmatory Phase 3 HARMONIA trial.”

Dyne Therapeutics Inc. (NASDAQ:DYN) is a biotechnology company that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. It uses its FORCE platform to identify the root cause of a condition and currently has a strong pipeline of clinical and preclinical programs.

2. Praxis Precision Medicines Inc. (NASDAQ:PRAX)

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best AI driven biotech stocks to invest in.

On June 2, BTIG reduced the price target on Praxis Precision Medicines Inc. (NASDAQ:PRAX) from $843 to $810. The firm maintained a Buy rating on the stock, informing investors that although the company’s Phase 2/3 POWER1 trial of vormatrigine resulted in a revenue loss, there is still hope for a recovery for the program.

Approximately 90% of patients in the vormatrigine-arm moved into the open-label extension and stayed there; the 50% rate of response secondary indicator met the criteria, seizure diminution was more noticeable in the remainder of the study on the increased 30 mg dose, and detrimental event-related withdrawals had been less than 10%.

Back on May 13, Truist Financial increased the price target from $700 to $715 while assuming a Buy rating for Praxis Precision Medicines Inc. (NASDAQ:PRAX). Truist highlighted that over the next six to eight months, the company is well-positioned for many value-inflecting events.

This positive outlook is supported by the strong late-stage pipeline of de-risked assets. The firm also pointed out that Praxis’s late-stage portfolio may grow into a franchise worth billions of dollars.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is involved in developing therapies to cure disorders related to the central nervous system, which are characterized by neuronal excitation-inhibition imbalance. These disorders include epilepsy, movement disorders, and depression. The company utilizes its proprietary platforms like Cerebrum and Solidus to target such imbalances.

1. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best AI driven biotech stocks to invest in.

As of the June 5 close, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) had a strongly bullish consensus sentiment. Based on a 1-year target price of $88.14, the stock offers an upside potential of more than 167%% at the prevailing level. It received Buy ratings from all 8 analysts who provided coverage.

On June 2, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) revealed that the company will be sharing data across 6 different presentations during the Endocrine Society’s Annual Meeting, ENDO 2026, in mid-June. Three of those presentations will be around PALSONIFY, which will incorporate data on long-term safety and efficacy from the open-label extension (OLE) studies, i.e., PATHFNDR-1 and PATHFNDR-2.

Besides that, there will be three presentations around the company’s atumelnant clinical development program. The company will share data from the Phase 2 study on congenital adrenal hyperplasia (CAH), along with Phase 1b/2a results for ACTH-dependent Cushing’s syndrome.

Back on May 15, Gavin Clark-Gartner from Evercore ISI reduced his target price for Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) from $89 to $88, resulting in an adjusted upside potential in excess of 167%. The firm maintained its Outperform rating on the stock.

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.